New combo aims at breast cancers that slip past current treatments
NCT ID NCT05633979
First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This early-phase trial tests a combination of two drugs—valemetostat and trastuzumab deruxtecan—in 17 people with metastatic breast cancer that has low, ultra-low, or no HER2 protein. The goal is to find a safe dose and see if the combo can shrink tumors. It's a small, first-in-human study, so results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- valemetostat and trastuzumab deruxtecan
- What this could lead to
- If it works, this combination could offer a new treatment option for people with hard-to-treat HER2-low or HER2-null metastatic breast cancer.
- What could go wrong
- This is a very early, small Phase 1b trial with only 17 participants, focused on finding a safe dose. It may not lead to a proven treatment, and side effects from the combination are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?